Showing 5101-5110 of 5771 results for "".
- Zeiss Marks Milestone for its New North America High Tech Site in Dublin, Californiahttps://modernod.com/news/zeiss-marks-milestone-for-its-new-north-america-high-tech-site-in-dublin-california/2476730/Zeiss announced that it has completed the “steel topping out” phase of its new high tech site in the San Francisco Bay Area. The new center will encompass 208,650 square feet with three floors. It is scheduled for completion in the fourth quarter of 2020 and will bring together multiple Ze
- Market Scope: Booming Demand, Surgical Planning Integration Drive Growth in Ophthalmic Diagnostic Markethttps://modernod.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/Market Scope estimates that the ophthalmic diagnostic equipment market will total $3.2 billion in 2019, and the firm expects it to increase to $3.8 billion in 2024—for a compound annual growth rate of 3.9 percent. Contributing factors include a rising global population, with an expanding elderly
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- SparingVision Awarded €2.5 Million at EIC Accelerator Programhttps://modernod.com/news/sparingvision-awarded-e2-5-million-at-eic-accelerator-program/2476715/SparingVision announced that it has been awarded non-dilutive funding of €2.5 million to fund research into retinitis pigmentosa therapies. SparingVision submitted a winning proposal for the European EIC Accelerator (SME instrument phase 2) program. The funding will help speed up SparingVi
- Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-submits-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease/2476716/Horizon Therapeutics announced that it has submitted a biologics license application (BLA) to the FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has breakthrough therapy, orphan drug and fast track designations from the FDA. H
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- Nicox Receives $3 Million Milestone Payment From Eyevance for Zerviate in the UShttps://modernod.com/news/nicox-receives-3-million-milestone-payment-from-eyevance-for-zerviate-in-the-us/2479567/Nicox SA announced that it has received a $3 million milestone payment from partner Eyevance Pharmaceuticals after completion of the regulatory and manufacturing activities. Nicox and Eyevance entered into a licensing agreement for Zerviate in the United States in September 2017 in which N
- Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Phase 2 Clinical Trial in Japan Ahead of Schedulehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-the-netarsudil-phase-2-clinical-trial-in-japan-ahead-of-schedule/2479568/Aerie Pharmaceuticals announced that enrollment for its phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated. The first patients to enter this prospective, double-masked, multicenter, placebo-
- Zeiss Receives FDA Clearance for Clarus 700 Ultra-Widefield Imaging Devicehttps://modernod.com/news/zeiss-receives-fda-clearance-for-clarus-700-ultra-widefield-imaging-device/2479571/Zeiss announced that it has received FDA 510(K) clearance for the Clarus 700, high-definition, ultra-widefield imaging system. Clarus 700 is the first high-resolution ultra-widefield imaging with true color and a comp